Partial
Mostly Aligned
Patient Risk:
Low
Summary
Efficacy-oriented claims align with mechanism and partial-onset/generalized seizure data but include numerous unsupported or overextended efficacy statements. Notable safety-labeling gaps exist (contraindications, boxed warnings, pregnancy data, and explicit pediatric safety details) based on the supplied sections.
Category Scores
Accurate Statements
Lacosamide is a sodium channel modulator.
12.1
Lacosamide is used for partial-onset seizures.
1.1, 14.2
Lacosamide selectively enhances slow inactivation of voltage-gated sodium channels.
12.1
Lacosamide is effective in focal, generalized, and refractory seizures.
1.1, 14.3
Start dose 100-200 mg/day and titrate.
2.1
Unsupported Statements
Lacosamide pairs well with drugs targeting GABA, calcium channels, or other pathways.
No explicit statements in the labeling about drug pairing or synergy beyond adjunctive therapy.
Combining lacosamide with other anticonvulsants reduces seizure frequency more effectively than single agents.
Label discusses adjunctive therapy versus placebo, not a direct comparison to monotherapy.
In drug-resistant focal epilepsy, adding lacosamide to 1-3 prior anticonvants achieved ≥50% seizure reduction in 41-60% of cases.
Adjunctive data show around 40% responders at certain doses; 41-60% is not supported by the cited trials.
Adding lacosamide has higher seizure reduction rates compared with monotherapy.
No direct monotherapy vs add-on comparison provided in the labeled trials.
When paired with levetiracetam or carbamazepine, 60-69% of patients became seizure-free or saw major improvements.
No data in labeling to support these percentages.
Lacosamide has sustained benefits over 2+ years in long-term data.
No explicit long-term 2+ year data described in the provided label sections.
Lacosamide paired with levetiracetam shows synergy via GABA modulation; trials report 53% median seizure reduction.
No such synergy or 53% median reduction data in the labeled sections.
Lacosamide combined with carbamazepine or lamotrigine provides enhanced control without pharmacokinetic clashes.
No labeling data describing pharmacokinetic interactions in this combination context.
Add-on studies show 41% responder rate with lacosamide plus carbamazepine or lamotrigine.
No such responder-rate data in the cited sections.
Lacosamide with valproate or topiramate improves outcomes in refractory cases.
No labeling data supporting this specific combination effect.
The combination reduces the need for dose escalation.
No labeling data supporting this claim.
The combination preserves tolerability.
No labeling data supporting this claim.
In refractory epilepsy patients failing 2+ prior drugs, 38-64% respond to lacosamide add-on.
Label indicates different responder data; the 38-64% range is not specifically supported.
In pediatric patients aged 4+, lacosamide add-on has 40-50% efficacy.
Pediatric efficacy data beyond 4+ years are not provided in the cited sections.
IV lacosamide plus anesthetics terminates seizures faster in some ICU cases of status epilepticus.
No such data in the presented label sections.
Lacosamide plus Levetiracetam shows high synergy and few interactions.
No labeling data on this specific combination synergy or interactions.
Lacosamide plus Levetiracetam yields 53% median seizure reduction.
No such data in labeling.
Lacosamide plus Carbamazepine achieves stable levels and rapid onset.
No labeling data describing this pharmacokinetic outcome.
Lacosamide plus Carbamazepine or lamotrigine shows 41-57% responders.
No labeling data providing this responder rate for these combinations.
Lacosamide plus Valproate is effective in generalized seizures.
No labeling data supporting this combination-specific efficacy.
Lacosamide plus Valproate yields 50%+ seizure reduction in trials.
No labeling data providing this figure.
Lacosamide plus Lamotrigine tolerable in focal epilepsy.
No labeling data describing tolerability of this combination.
Lacosamide plus Lamotrigine yields 40-60% improvement.
No labeling data providing this figure.
Dizziness occurs in 20-30% of patients taking lacosamide.
Adverse event frequencies are not detailed in the provided label sections.
Nausea occurs with lacosamide.
Adverse event frequencies are not detailed in the provided label sections.
Rare cardiac effects occur with lacosamide.
No explicit statement about rare cardiac effects in the provided sections.
Monitor ECG in patients with heart disease.
No direct monitoring instruction present in the cited sections.
Lacosamide is not first-line; use after monotherapy failure per guidelines.
Label sections do not explicitly state a non-first-line designation.
Contradictions
Low
AI Statement
In seniors, lacosamide has reduced dosing.
Label Reference
8.5
Important Omissions
Contraindications (e.g., hypersensitivity) are not specified in the claims.
Importance:
High
Boxed warnings are not identified in the claims; verify presence in labeling.
Importance:
High
Dosing safety details beyond start dose (max daily dose, renal/hepatic adjustments) are not provided.
Importance:
High
Pregnancy risk and fetal outcomes labeling (often category) are not addressed in the claims.
Importance:
High
Pediatric safety data and dosing specifics beyond the 4+ weight-based guidance are not explicit.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
Efficacy claims align with labeled adjunctive data; however, several safety-critical elements (contraindications, boxed warnings, pregnancy, detailed pediatric safety) are not demonstrated by the provided claims.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement